Enhancing the Scientific Integrity and Safety of Clinical Trials: Recommendations for Data Monitoring Committees
Lewis et al talk about the risks of participating in a clinical trial which cannot be predicted with certainty at the time of trial design, especially when evaluating novel therapies. Accordingly, once the trial is initiated, periodic and ongoing review of accumulating study data is necessary to ens...
Gespeichert in:
| Veröffentlicht in: | JAMA : the journal of the American Medical Association 2016-12, Vol.316 (22), p.2359-2360 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2360 |
|---|---|
| container_issue | 22 |
| container_start_page | 2359 |
| container_title | JAMA : the journal of the American Medical Association |
| container_volume | 316 |
| creator | Lewis, Roger J Calis, Karim A DeMets, David L |
| description | Lewis et al talk about the risks of participating in a clinical trial which cannot be predicted with certainty at the time of trial design, especially when evaluating novel therapies. Accordingly, once the trial is initiated, periodic and ongoing review of accumulating study data is necessary to ensure the continued appropriateness of enrolling and treating patients in the trial. |
| doi_str_mv | 10.1001/jama.2016.16070 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1852677723</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><ama_id>2592508</ama_id><sourcerecordid>1852677723</sourcerecordid><originalsourceid>FETCH-LOGICAL-a298t-af0badb5ca1c121b79a4e314d9aab5bfe7bd87b086f6b96a29a2978f7c58f2ec3</originalsourceid><addsrcrecordid>eNpdkc1r3DAQxUVpaTZpz4EciiCXXLyR5LUl9xY2Hw2kFJr0bEbyKNFiS1tJe8h_X7mb5JBBMCP0e49Bj5BjzpacMX6-gQmWgvF2yVsm2Qey4E2tqrrp1EeyYKxTlVyp1QE5TGnDSvFafiYHQnbtfFmQ7ZV_Am-cf6T5Cem9ceizs87QW5_xMbr8TMEP9B4sljFYuh6ddwZG-hAdjOk7_Y0mTBP6AbILPlEbIr2EDPRn8C6HOHuvC-FyRkxfyCdbZPj1pR-RP9dXD-sf1d2vm9v1xV0FolO5Ass0DLoxwA0XXMsOVljz1dAB6EZblHpQUjPV2lZ3bRGVI5WVplFWoKmPyNnedxvD3x2m3E8uGRxH8Bh2qeeqEa2UUtQFPX2HbsIu-rLdTNVSSNXO1PmeMjGkFNH22-gmiM89Z_0cRj-H0c9h9P_DKIpvL747PeHwxr_-fgFO9sAsfHttOtEwVf8DOAuPTQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1853727863</pqid></control><display><type>article</type><title>Enhancing the Scientific Integrity and Safety of Clinical Trials: Recommendations for Data Monitoring Committees</title><source>MEDLINE</source><source>American Medical Association Journals</source><creator>Lewis, Roger J ; Calis, Karim A ; DeMets, David L</creator><creatorcontrib>Lewis, Roger J ; Calis, Karim A ; DeMets, David L</creatorcontrib><description>Lewis et al talk about the risks of participating in a clinical trial which cannot be predicted with certainty at the time of trial design, especially when evaluating novel therapies. Accordingly, once the trial is initiated, periodic and ongoing review of accumulating study data is necessary to ensure the continued appropriateness of enrolling and treating patients in the trial.</description><identifier>ISSN: 0098-7484</identifier><identifier>EISSN: 1538-3598</identifier><identifier>DOI: 10.1001/jama.2016.16070</identifier><identifier>PMID: 27960001</identifier><identifier>CODEN: JAMAAP</identifier><language>eng</language><publisher>United States: American Medical Association</publisher><subject>Clinical trials ; Clinical Trials as Topic - ethics ; Clinical Trials as Topic - standards ; Clinical Trials Data Monitoring Committees ; Patient Safety ; Risk ; Therapy ; Treatment Outcome</subject><ispartof>JAMA : the journal of the American Medical Association, 2016-12, Vol.316 (22), p.2359-2360</ispartof><rights>Copyright American Medical Association Dec 13, 2016</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://jamanetwork.com/journals/jama/articlepdf/10.1001/jama.2016.16070$$EPDF$$P50$$Gama$$H</linktopdf><linktohtml>$$Uhttps://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2016.16070$$EHTML$$P50$$Gama$$H</linktohtml><link.rule.ids>64,314,780,784,3340,27924,27925,76489,76492</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27960001$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lewis, Roger J</creatorcontrib><creatorcontrib>Calis, Karim A</creatorcontrib><creatorcontrib>DeMets, David L</creatorcontrib><title>Enhancing the Scientific Integrity and Safety of Clinical Trials: Recommendations for Data Monitoring Committees</title><title>JAMA : the journal of the American Medical Association</title><addtitle>JAMA</addtitle><description>Lewis et al talk about the risks of participating in a clinical trial which cannot be predicted with certainty at the time of trial design, especially when evaluating novel therapies. Accordingly, once the trial is initiated, periodic and ongoing review of accumulating study data is necessary to ensure the continued appropriateness of enrolling and treating patients in the trial.</description><subject>Clinical trials</subject><subject>Clinical Trials as Topic - ethics</subject><subject>Clinical Trials as Topic - standards</subject><subject>Clinical Trials Data Monitoring Committees</subject><subject>Patient Safety</subject><subject>Risk</subject><subject>Therapy</subject><subject>Treatment Outcome</subject><issn>0098-7484</issn><issn>1538-3598</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkc1r3DAQxUVpaTZpz4EciiCXXLyR5LUl9xY2Hw2kFJr0bEbyKNFiS1tJe8h_X7mb5JBBMCP0e49Bj5BjzpacMX6-gQmWgvF2yVsm2Qey4E2tqrrp1EeyYKxTlVyp1QE5TGnDSvFafiYHQnbtfFmQ7ZV_Am-cf6T5Cem9ceizs87QW5_xMbr8TMEP9B4sljFYuh6ddwZG-hAdjOk7_Y0mTBP6AbILPlEbIr2EDPRn8C6HOHuvC-FyRkxfyCdbZPj1pR-RP9dXD-sf1d2vm9v1xV0FolO5Ass0DLoxwA0XXMsOVljz1dAB6EZblHpQUjPV2lZ3bRGVI5WVplFWoKmPyNnedxvD3x2m3E8uGRxH8Bh2qeeqEa2UUtQFPX2HbsIu-rLdTNVSSNXO1PmeMjGkFNH22-gmiM89Z_0cRj-H0c9h9P_DKIpvL747PeHwxr_-fgFO9sAsfHttOtEwVf8DOAuPTQ</recordid><startdate>20161213</startdate><enddate>20161213</enddate><creator>Lewis, Roger J</creator><creator>Calis, Karim A</creator><creator>DeMets, David L</creator><general>American Medical Association</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QP</scope><scope>7TK</scope><scope>7TS</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>20161213</creationdate><title>Enhancing the Scientific Integrity and Safety of Clinical Trials: Recommendations for Data Monitoring Committees</title><author>Lewis, Roger J ; Calis, Karim A ; DeMets, David L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a298t-af0badb5ca1c121b79a4e314d9aab5bfe7bd87b086f6b96a29a2978f7c58f2ec3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Clinical trials</topic><topic>Clinical Trials as Topic - ethics</topic><topic>Clinical Trials as Topic - standards</topic><topic>Clinical Trials Data Monitoring Committees</topic><topic>Patient Safety</topic><topic>Risk</topic><topic>Therapy</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lewis, Roger J</creatorcontrib><creatorcontrib>Calis, Karim A</creatorcontrib><creatorcontrib>DeMets, David L</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Physical Education Index</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>JAMA : the journal of the American Medical Association</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lewis, Roger J</au><au>Calis, Karim A</au><au>DeMets, David L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Enhancing the Scientific Integrity and Safety of Clinical Trials: Recommendations for Data Monitoring Committees</atitle><jtitle>JAMA : the journal of the American Medical Association</jtitle><addtitle>JAMA</addtitle><date>2016-12-13</date><risdate>2016</risdate><volume>316</volume><issue>22</issue><spage>2359</spage><epage>2360</epage><pages>2359-2360</pages><issn>0098-7484</issn><eissn>1538-3598</eissn><coden>JAMAAP</coden><abstract>Lewis et al talk about the risks of participating in a clinical trial which cannot be predicted with certainty at the time of trial design, especially when evaluating novel therapies. Accordingly, once the trial is initiated, periodic and ongoing review of accumulating study data is necessary to ensure the continued appropriateness of enrolling and treating patients in the trial.</abstract><cop>United States</cop><pub>American Medical Association</pub><pmid>27960001</pmid><doi>10.1001/jama.2016.16070</doi><tpages>2</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0098-7484 |
| ispartof | JAMA : the journal of the American Medical Association, 2016-12, Vol.316 (22), p.2359-2360 |
| issn | 0098-7484 1538-3598 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1852677723 |
| source | MEDLINE; American Medical Association Journals |
| subjects | Clinical trials Clinical Trials as Topic - ethics Clinical Trials as Topic - standards Clinical Trials Data Monitoring Committees Patient Safety Risk Therapy Treatment Outcome |
| title | Enhancing the Scientific Integrity and Safety of Clinical Trials: Recommendations for Data Monitoring Committees |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T05%3A33%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Enhancing%20the%20Scientific%20Integrity%20and%20Safety%20of%20Clinical%20Trials:%20Recommendations%20for%20Data%20Monitoring%20Committees&rft.jtitle=JAMA%20:%20the%20journal%20of%20the%20American%20Medical%20Association&rft.au=Lewis,%20Roger%20J&rft.date=2016-12-13&rft.volume=316&rft.issue=22&rft.spage=2359&rft.epage=2360&rft.pages=2359-2360&rft.issn=0098-7484&rft.eissn=1538-3598&rft.coden=JAMAAP&rft_id=info:doi/10.1001/jama.2016.16070&rft_dat=%3Cproquest_cross%3E1852677723%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1853727863&rft_id=info:pmid/27960001&rft_ama_id=2592508&rfr_iscdi=true |